September 25, 2024
Potent and Selective Oral STAT6 Degrader, KT-621, Inhibits IL-4 and IL-13 Functions in Human Cells and Blocks TH2 Inflammation In Vivo
European Academy of Dermatology and Venereology (EADV) 2024
Read More
August 16, 2024
Journal of Medicinal Chemistry: Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases
Zheng, et al.
Read More
July 29, 2024
Journal of Investigative Dermatology: Interleukin 1 Receptor–Associated Kinase 4 is Overexpressed in Hidradenitis Suppurativa Skin and Correlates with Inflammatory Biomarkers
McDonald, et al.
Hidradenitis Suppurativa (HS)
Read More
June 26, 2024
Journal of Medicinal Chemistry: Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma
Weiss, et al.
Read More
June 14, 2024
Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Hematologic and Solid Tumor Cancers
European Hematology Association (EHA) 2024
cHL
CTCL
Liquid Tumors
Solid Tumors
Read More
June 1, 2024
Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of KT-253, a Targeted Protein Degrader of MDM2, in Patients with Relapsed/Refractory (R/R) Solid Tumors, Lymphoma, High Grade Myeloid Malignancies and Acute Lymphoblastic Leukemia (ALL)
American Society of Clinical Oncology (ASCO) 2024
Liquid Tumors
Solid Tumors
Read More
May 22, 2024
Potent and Selective Oral STAT6 Degraders Inhibit IL-4 and IL-13 Functions in Human Cells and Block TH2 Inflammation in a House Dust Mite Model of Asthma
American Thoracic Society (ATS) 2024
Read More
May 21, 2024
Potent and Selective Oral STAT6 Degraders Inhibit IL-4 and IL-13 Functions in Human Cells and Block TH2 Inflammation In Vivo in a Mouse Model
Digestive Disease Week (DDW) 2024
Read More
April 7, 2024
E3 Pairing and Structural Mechanisms Underlying Anti-Tumor Activity of Clinical STAT3 Degrader KT-333
American Association for Cancer Research (AACR) 2024 Annual Meeting
Read More
March 8, 2024
Potent and Selective TYK2 degraders, Devoid of JAK Activity, Potently and Completely Suppress IL12/23 and Type I IFN Signaling Pathways
American Academy of Dermatology (AAD) 2024 Annual Meeting
Read More